Search
Nov 7
Texas Life Science Forum: March Biosciences closed a $28.4M series A round last month to advance its CD5 targeting CAR-T
CEO Sarah Hein describes the rationale for CD5, and share her experience of what it was like making the raise come together. Brought to...
Sep 23, 2023
An entrepreneur describes launching a cell therapy startup in Houston
March Biosciences’ CEO Sarah Hein on the infrastructure available in Houston for biotech startups, and the science behind her CD5 CAR-T.